rethinkTHC Search
Menu
Study breakdown

Several Medications Show Promise for Treating Cannabis Use Disorder

ReviewModerate evidence
The takeaway

A review of randomized controlled trials found multiple medications, including CBD, gabapentin, nabiximols, and others, showed superiority over placebo for cannabis use disorder, though all need further validation.

Addiction medicine specialists, psychiatrists, and CUD researchers

10 medications showed some benefit for CUD across RCTs

What the researchers found

Across multiple pharmacological systems, CBD, gabapentin, galantamine, nabilone plus zolpidem, nabiximols, naltrexone, PF-04457845 (FAAH inhibitor), quetiapine, varenicline, and topiramate all showed some superiority over control conditions in RCTs for CUD. All were reported as safe and tolerable.

Why it matters

There is currently no FDA-approved medication for cannabis use disorder, despite the condition affecting roughly one in five cannabis users. This review maps the entire landscape of pharmacological candidates that have reached the RCT stage.

The numbers in context

About 1 in 5 cannabis users develop CUD, rising to 1 in 2 for daily users. CUD accounts for 0.69 million disability-adjusted life years globally. Ten medication classes showed some benefit across eight neurotransmitter systems.

How the study worked

Narrative review of randomized controlled trials examining pharmacological interventions for cannabis use disorder, organized by mechanism of action across cannabinoid, glutamatergic, GABAergic, serotonergic, noradrenergic, dopaminergic, opioidergic, and cholinergic systems.

What this study cannot tell us

Narrative review without formal meta-analysis. Individual RCTs varied in sample size, follow-up duration, and outcome measures. Many trials had small samples. "Superiority over control" ranged from modest to meaningful effects.

How to read the evidence

Narrative review synthesizing RCT evidence, which provides a broad overview but lacks the rigor of a systematic review or meta-analysis.

When this study was published

2024 review

The bigger picture

The diversity of promising targets across multiple neurotransmitter systems suggests CUD is not a single-mechanism disorder. The field is moving toward combining pharmacotherapy with psychotherapy, and drug repurposing offers faster paths to clinical availability than new drug development.

Questions still open

  • Which of these medications will prove most effective in larger confirmatory trials? Can combinations of medications targeting different systems produce better outcomes? Will personalized approaches based on patient characteristics improve treatment matching?

Common questions

Are there medications for cannabis use disorder?
There is no FDA-approved medication yet, but this review found 10 medications (including CBD, gabapentin, nabiximols, and topiramate) that showed some benefit in randomized controlled trials.
What is the best treatment approach for CUD?
According to this review, combining pharmacotherapy with psychotherapy appears to be the optimal approach, tailored on a case-by-case basis.

Read the original research

Emerging pharmacotherapy for the treatment of cannabis use disorder.

Expert opinion on pharmacotherapy, 25(6), 695-703

Citation

Shamabadi, Ahmad; Arabzadeh Bahri, Razman; Karimi, Hanie; Heidari, Ehsan; Akhondzadeh, Shahin. (2024). Emerging pharmacotherapy for the treatment of cannabis use disorder.. Expert opinion on pharmacotherapy, 25(6), 695-703. https://doi.org/10.1080/14656566.2024.2353638

Explore the wider topic